Table 9Characteristics of head-to-head studies comparing leukotriene modifiers in children and adults

StudyStudy design
N
Duration
Country
Study population
Setting
Comparison (total daily dose in mg/day)Quality rating
Montelukast (ML) compared with zafirlukast
Riccioni et al.72RCT

40

12 weeks
Italy

Age ≥ 12, mild, smoking status NR

Respiratory Pathophysiology Center
ML (10) compared with ZAF (40)Fair
Montelukast compared with zileuton
No systematic reviews or head-to-head trials found
Zafirlukast compared with zileuton
No systematic reviews or head-to-head trials found

Abbreviations: AQLQ = Asthma Quality of Life Questionnaire; ML = Montelukast; NR = not reported; NS = not stati, stically significant; RCT= randomized controlled trial; ZAF = Zafirlukast.

Symbol use: Drug X > Drug Y = statistically significant difference in outcomes favoring Drug X;

Drug X > Drug Y trend = point estimate favors Drug X, but the difference is not statistically significant or tests of statistical significance were NR;

No difference = no statistically significant difference or tests of statistical significance were not reported and outcomes are similar.

From: Results

Cover of Drug Class Review: Controller Medications for Asthma
Drug Class Review: Controller Medications for Asthma: Final Update 1 Report [Internet].
Jonas DE, Wines RCM, DelMonte M, et al.
Portland (OR): Oregon Health & Science University; 2011 Apr.
Copyright © 2011 by Oregon Health & Science University.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.